BACKGROUND:Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization. OBJECTIVE: To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain. METHODS: A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated. RESULTS: The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers' willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency. CONCLUSIONS:Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.
RCT Entities:
BACKGROUND:Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization. OBJECTIVE: To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain. METHODS: A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated. RESULTS: The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers' willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency. CONCLUSIONS:Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.
Authors: Peter H Stone; Nikolay A Gratsiansky; Alexey Blokhin; I-Zu Huang; Lixin Meng Journal: J Am Coll Cardiol Date: 2006-06-15 Impact factor: 24.094
Authors: David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Sabina A Murphy; Andrzej Budaj; Sergei Varshavsky; Andrew A Wolff; Allan Skene; Carolyn H McCabe; Eugene Braunwald Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: Bernard R Chaitman; Sandra L Skettino; John O Parker; Peter Hanley; Jaroslav Meluzin; Jerzy Kuch; Carl J Pepine; Whedy Wang; Jeanenne J Nelson; David A Hebert; Andrew A Wolff Journal: J Am Coll Cardiol Date: 2004-04-21 Impact factor: 24.094
Authors: Suzanne V Arnold; David A Morrow; Kaijun Wang; Yang Lei; Elizabeth M Mahoney; Benjamin M Scirica; Eugene Braunwald; David J Cohen Journal: Circ Cardiovasc Qual Outcomes Date: 2008-11-05
Authors: Suzanne V Arnold; David A Morrow; Yang Lei; David J Cohen; Elizabeth M Mahoney; Eugene Braunwald; Paul S Chan Journal: Circ Cardiovasc Qual Outcomes Date: 2009-06-02
Authors: Carlos A Salazar; Juan E Basilio Flores; Liz E Veramendi Espinoza; Jhon W Mejia Dolores; Diego E Rey Rodriguez; César Loza Munárriz Journal: Cochrane Database Syst Rev Date: 2017-02-08
Authors: Georgia Kourlaba; Charalambos Vlachopoulos; John Parissis; John Kanakakis; George Gourzoulidis; Nikos Maniadakis Journal: BMC Health Serv Res Date: 2015-12-18 Impact factor: 2.655
Authors: Georgia Kourlaba; George Gourzoulidis; George Andrikopoulos; Konstantinos Tsioufis; Alexandra Beletsi; Nikos Maniadakis Journal: BMC Health Serv Res Date: 2016-09-27 Impact factor: 2.655